Vicore Pharma Holding AB (publ) (VICO.ST)
SEK 7.77
(1.17%)
SEK 7.77
(1.17%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -321.5 Million SEK | -10.59% |
| 2022 | -290.72 Million SEK | 1.39% |
| 2021 | -294.81 Million SEK | -97.15% |
| 2020 | -149.53 Million SEK | -59.06% |
| 2019 | -94.01 Million SEK | -112.32% |
| 2018 | -44.28 Million SEK | -246.13% |
| 2017 | -12.79 Million SEK | -92.4% |
| 2016 | -6.64 Million SEK | -46.36% |
| 2015 | -4.54 Million SEK | 14.93% |
| 2014 | -5.34 Million SEK | -78.3% |
| 2013 | -2.99 Million SEK | -168063.95% |
| 2012 | -1781.00 SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 26.17 Million SEK | 121.66% |
| 2024 Q2 | -62.73 Million SEK | -339.67% |
| 2023 Q4 | -120.81 Million SEK | -85.71% |
| 2023 Q1 | -66.08 Million SEK | -4.81% |
| 2023 Q2 | -69.79 Million SEK | -5.62% |
| 2023 FY | -320.88 Million SEK | -10.38% |
| 2023 Q3 | -65.05 Million SEK | 6.79% |
| 2022 Q1 | -93.17 Million SEK | -14.9% |
| 2022 Q2 | -64.85 Million SEK | 30.39% |
| 2022 FY | -290.72 Million SEK | 1.39% |
| 2022 Q3 | -69.65 Million SEK | -7.39% |
| 2022 Q4 | -63.04 Million SEK | 9.48% |
| 2021 Q1 | -47.53 Million SEK | 19.22% |
| 2021 Q4 | -81.08 Million SEK | 17.05% |
| 2021 Q3 | -97.75 Million SEK | -42.84% |
| 2021 Q2 | -68.43 Million SEK | -43.98% |
| 2021 FY | -294.81 Million SEK | -97.15% |
| 2020 FY | -149.53 Million SEK | -59.06% |
| 2020 Q1 | -28.78 Million SEK | 4.83% |
| 2020 Q3 | -34.44 Million SEK | -25.37% |
| 2020 Q4 | -58.84 Million SEK | -70.84% |
| 2020 Q2 | -27.47 Million SEK | 4.55% |
| 2019 FY | -94.01 Million SEK | -112.32% |
| 2019 Q4 | -30.24 Million SEK | -32.45% |
| 2019 Q3 | -22.83 Million SEK | 8.07% |
| 2019 Q2 | -24.83 Million SEK | -54.31% |
| 2019 Q1 | -16.09 Million SEK | 42.58% |
| 2018 Q4 | -28.03 Million SEK | -337.7% |
| 2018 Q3 | -6.4 Million SEK | -14.27% |
| 2018 Q1 | -4.23 Million SEK | 32.57% |
| 2018 FY | -44.28 Million SEK | -246.13% |
| 2018 Q2 | -5.6 Million SEK | -32.35% |
| 2017 FY | -12.79 Million SEK | -92.4% |
| 2017 Q4 | -6.28 Million SEK | -272.76% |
| 2017 Q3 | -1.68 Million SEK | 26.74% |
| 2017 Q2 | -2.3 Million SEK | 6.35% |
| 2017 Q1 | -2.45 Million SEK | -36.29% |
| 2016 Q1 | -1.91 Million SEK | -39.97% |
| 2016 FY | -6.64 Million SEK | -46.36% |
| 2016 Q3 | -1.58 Million SEK | -18.34% |
| 2016 Q2 | -1.34 Million SEK | 30.12% |
| 2016 Q4 | -1.8 Million SEK | -13.55% |
| 2015 Q1 | -1.12 Million SEK | 27.95% |
| 2015 FY | -4.54 Million SEK | 14.93% |
| 2015 Q2 | -1.09 Million SEK | 3.37% |
| 2015 Q4 | -1.37 Million SEK | -44.01% |
| 2015 Q3 | -952 Thousand SEK | 12.74% |
| 2014 Q4 | -1.56 Million SEK | -106.18% |
| 2014 Q3 | -760 Thousand SEK | 42.36% |
| 2014 FY | -5.34 Million SEK | -78.3% |
| 2014 Q2 | -1.31 Million SEK | 0.0% |
| 2014 Q1 | -1.31 Million SEK | -133.78% |
| 2013 Q1 | -568.50 SEK | 29.2% |
| 2013 Q3 | -412 Thousand SEK | 27.53% |
| 2013 Q4 | -564 Thousand SEK | -36.89% |
| 2013 FY | -2.99 Million SEK | -168063.95% |
| 2013 Q2 | -568.5 Thousand SEK | -99900.0% |
| 2012 Q3 | -352.00 SEK | 0.0% |
| 2012 Q4 | -803.00 SEK | -128.13% |
| 2012 FY | -1781.00 SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | -29.128% |
| Ziccum AB (publ) | -21.56 Million SEK | -1391.215% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -1860.283% |
| BioArctic AB (publ) | 252.64 Million SEK | 227.259% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -37948.047% |
| Mendus AB (publ) | -100.65 Million SEK | -219.43% |
| Genovis AB (publ.) | 54.22 Million SEK | 692.922% |
| Intervacc AB (publ) | -93.57 Million SEK | -243.566% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -1972.628% |
| Active Biotech AB (publ) | -46.48 Million SEK | -591.649% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 1885.252% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | -480.158% |
| Aptahem AB (publ) | -10.1 Million SEK | -3081.728% |
| Kancera AB (publ) | -65.04 Million SEK | -394.305% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | -138.83% |
| Fluicell AB (publ) | -26.87 Million SEK | -1096.123% |
| Saniona AB (publ) | -81.06 Million SEK | -296.603% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -2498.868% |
| Biovica International AB (publ) | -126.07 Million SEK | -155.016% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -656.396% |
| AcouSort AB (publ) | -17.48 Million SEK | -1738.543% |
| Xintela AB (publ) | -57.23 Million SEK | -461.7% |
| Abliva AB (publ) | -96.54 Million SEK | -233.001% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 1.014% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -9072.782% |
| OncoZenge AB (publ) | -15.9 Million SEK | -1921.796% |
| Amniotics AB (publ) | -29.07 Million SEK | -1005.858% |
| 2cureX AB (publ) | -36.36 Million SEK | -784.157% |
| CombiGene AB (publ) | -36.3 Million SEK | -785.566% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -2096.079% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 16.361% |
| Camurus AB (publ) | 532.35 Million SEK | 160.393% |
| Corline Biomedical AB | -1.78 Million SEK | -17881.32% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | -77.859% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -671.312% |
| I-Tech AB | 24.43 Million SEK | 1415.76% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 59.225% |
| Cyxone AB (publ) | -21.66 Million SEK | -1384.262% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | -203.408% |
| Biosergen AB | -27.26 Million SEK | -1079.189% |
| Cantargia AB (publ) | -290.01 Million SEK | -10.858% |
| NextCell Pharma AB | -43.17 Million SEK | -644.707% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | -77.859% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -1780.561% |
| Nanologica AB (publ) | -69.96 Million SEK | -359.537% |
| SynAct Pharma AB | -224.49 Million SEK | -43.212% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | -627.784% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -1242.166% |
| LIDDS AB (publ) | -40.67 Million SEK | -690.446% |
| Lipum AB (publ) | -37.25 Million SEK | -763.011% |
| BioInvent International AB (publ) | -369.94 Million SEK | 13.093% |
| Alzinova AB (publ) | -16.52 Million SEK | -1845.927% |
| Oncopeptides AB (publ) | -253.44 Million SEK | -26.853% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -4928.836% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | -179.393% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -1496.435% |
| Simris Alg AB (publ) | -36.63 Million SEK | -777.592% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | -119.358% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | -3.569% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | -189.87% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -2679.751% |